Recent Updates
Recently added Catalysts

ALIS

Phase 3

Mycobacterium Infections, Nontuberculous | Small molecule | Infectious Disease |Insmed Incorporated|Last Updated: Feb 3, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials2
Total Enrollment524

FDA Designations

No designations recorded

Clinical trial landscape

ALIS · 2 trials · 1 indication

Phase 3 2
NCT04677569Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexMycobacterium Infections, Nontuberculous
COMPLETED425 Analytics
NCT04677543Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexMycobacterium Infections, Nontuberculous
COMPLETED99 Analytics
PHASE3COMPLETED
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Mycobacterium Infections, NontuberculousUnlock trial analytics
PHASE3COMPLETED
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Mycobacterium Infections, NontuberculousUnlock trial analytics

Study Endpoints

Primary Endpoints

Change from Baseline in Respiratory Symptom Score at Month 13
Baseline to Month 13
Psychometric Cross-Sectional Validation of Patient Reported Outcome (PRO): Patient Global Impression of Severity (PGI-S) Respiratory Scale Score at Baseline
Baseline

The PGI-S respiratory symptom is a self-reported scale to measure the severity of illness based on symptoms using a 5-point scale ranging from 1 to 5, (1=not at all, 2=mild, 3=moderate, 4=very severe, 5=extremely severe). Considering different aspects of breathing symptoms like congestion, cough, mucus, wheezing, shortness of breath, participants rated their symptom severity on the PGI-S respiratory symptom scale. Higher scores indicate greater symptom severity.

Psychometric Cross-Sectional Validation of PRO: PGI-S Fatigue Scale Score at Baseline
Baseline

The PGI-S fatigue is a self-reported scale to measure the severity of illness based on symptoms using a 5-point scale ranging from 1 to 5, (1=not at all, 2=mild, 3=moderate, 4=very severe, 5=extremely severe). Participants rated the severity of their fatigue on the PGI-S fatigue scale. Higher scores indicate greater fatigue severity.

Psychometric Cross-Sectional Validation of PRO: Quality of Life Questionnaire - Bronchiectasis (QoL-B) Respiratory Symptoms Scale Score at Baseline
Baseline

The QOL-B is a self-administered, PRO questionnaire used to assess symptoms, functioning, and health related quality of life in adults with lung conditions. The respiratory symptom domain of the QOL-B contains 9 items describing patient's self-assessment of her/his respiratory symptoms that affect daily life. For each of the 8 items (chest congestion, coughing, cough up mucus, shortness of breath with greater activity, wheezing, chest pain, shortness of breath when talking, woken up during night due to cough), scores ranged from 1 to 4 (1= lot, 2= moderate, 3= little, 4= not at all) and the sputum item based on the color ranged from 0=don't know,1=green with traces of blood/brownish dark,2=yellowish-green,3=clear to yellow,4=clear. The item scores were summed and then standardized on a 0 to 100-point scale to derive the domain score with higher scores representing fewer symptoms or better functioning and quality of life.

Psychometric Cross-Sectional Validation of PRO: Patient-Reported Outcome Measurement Information System - Fatigue-Short Form 7a (PROMIS F-SF 7a) Score at Baseline
Baseline

The PROMIS F-SF 7a is a self-administered questionnaire assessing a range of self-reported symptoms over the past 7 days, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities over 7 items. Response options are on a 5-point Likert scale, ranging from 1=never to 5=always. Total scores range from 7 to 35 and low scores represent less fatigue interference i.e., better symptoms.

Assessment of Test-Retest Reliability (TRTR) Reported as the Intraclass Co-relation (ICC) Estimate Among Participants Reporting no Change on Respiratory PGI-S Score Applied to QOL-B Respiratory Domain Score Between Screening and Baseline
From Screening to Baseline (Day -70 to Day 1)

TRTR consists of measuring the degree to which an instrument yield reproducible score at different points in time assessed across a fixed and common time interval for all subjects. TRTR co-relations were based on the two-way mixed effect ICC coefficient estimated using the inter-rater reliability package, version 0.84.1. TRTR estimate of 0.7 and above indicated better retest reliability. TRTR was assessed among participants reporting no change on PGI-S between screening and baseline. PGI-S anchors are PRO specific, with a respiratory PGI-S (scale ranging from 1=not at all to 5=extremely severe, Higher scores=greater symptom severity) applied to the QOL-B respiratory domain (9-item scale ranging from 0 to 100, higher scores=fewer symptoms and better quality of life). As pre-specified in statistical analysis plan(SAP) for participants contributing to this outcome measure from INS-415 study,data were collected and analyzed for combined population in which ALIS and ELC groups were pooled.

Assessment of TRTR Reported as the ICC Estimate Among Participants Reporting no Change on Fatigue PGI-S Score Applied to PROMIS F-SF 7a Score Between Screening and Baseline
From Screening to Baseline (Day -70 to Day 1)

TRTR consists of measuring the degree to which an instrument yield reproducible score at different points in time assessed across a fixed and common time interval for all subjects. TRTR co-relations were based on the two-way mixed effect ICC coefficient estimated using the inter-rater reliability package, version 0.84.1. TRTR estimate of 0.7 and above indicated better retest reliability. TRTR was estimated using mean PROMIS F-SF 7a scores from participants who were stable as defined by a PGI-S-Fatigue change score of zero between screening and baseline. As pre-specified in the SAP, for participants contributing to this outcome measure from INS-415 study, data were collected and analyzed for combined population in which ALIS and ELC groups were pooled.

Response Rate as Assessed by Within-Subject Meaningful Change (WSMC) for QOL-B Respiratory Symptoms Final Score Estimated Via Anchor-Based Methods and Validated Via Empirical Cumulative Distribution Functions (eCDFs)
Baseline to Month 7

WSMC was estimated via change scores computed between Baseline and end of study (EOS) (Month 7). The estimated WSMC threshold of 14.81 points for the QOL-B Respiratory Symptom score (9-item scale ranging from 0 to 100, higher scores=fewer symptoms and better quality of life) as derived from anchor-based methods supplemented with eCDF curves was used for analysis. The percentage of participants and confidence intervals were estimated by standardized logistic regression with treatment group and history of mycobacterium avium complex (MAC) lung infection as factors in the model. Missing change from baseline at Month 7 was imputed by multiple imputation. The mean of all imputed values was used to derive response according to WSMC. Response rate was expressed in terms of percentage of participants and the percentages are rounded off to the nearest decimal.

Response Rate as Assessed by WSMC for PROMIS Fatigue Final Score Estimated Via Anchor-Based Methods and Validated Via eCDFs
Baseline to Month 7

WSMC was estimated via change scores computed between Baseline and EOS (Month 7). The percentage of participants and confidence intervals were estimated by standardized logistic regression with treatment group and history of MAC lung infection as factors in the model. Missing change from baseline at Month 7 was imputed by multiple imputation. The mean of all imputed values was used to derive response according to WSMC. The estimated WSMC threshold of -4.00 points for the PROMIS Fatigue score as derived from anchor-based methods supplemented with eCDF curves was used for analysis. Response rate was expressed in terms of percentage of participants and the percentages are rounded off to the nearest decimal.

Secondary Endpoints

Percentage of Participants Achieving Durable Culture Conversion at Month 15
Month 15
Change from Baseline in Fatigue Symptom Score at Month 13
Baseline to Month 13
Percentage of Participants Achieving Culture Conversion by Month 6
Month 6
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ALIS + Background RegimenEXPERIMENTALParticipants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered azithromycin 250 mg and ethambutol 15 mg/kg, once daily.
ELC + Background RegimenPLACEBO_COMPARATORParticipants will be administered ELC (empty liposome control), a visually matching placebo to ALIS (amikacin liposome inhalation suspension), once daily. Participants will also be administered azithromycin 250 mg and ETH (ethambutol) 15 mg/kg, once daily.
ALIS + Background Regimen (Azithromycin + Ethambutol)ACTIVE_COMPARATORParticipants will be administered 590 mg of ALIS (amikacin liposome inhalation suspension) once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.
ELC + Background Regimen (Azithromycin + Ethambutol)PLACEBO_COMPARATORParticipants will be administered ELC (empty liposome control), a matching placebo to ALIS, once daily. Participants will also be administered the background regimen of azithromycin 250 mg and ethambutol 15 mg/kg tablets orally, once daily.

Interventions

NameTypeDescription
ALISDRUGInhalation via nebulization over approximately 6 to 15 minutes
AzithromycinDRUGOral tablet
EthambutolDRUGOral tablet
ELC (matching placebo for ALIS)DRUGInhalation via nebulization over approximately 6 to 15 minutes
ELCDRUGInhalation via nebulization over approximately 6 to 15 minutes.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites258

Inclusion Criteria: * Male or female, ≥ 18 years of age (19 years or older in South Korea, 20 years or older in Japan). * Current diagnosis of MAC lung infection. MAC or mixed infection with MAC as the dominant species is allowed, with MAC as the intended organism for treatment. * A chest computeri...

Countries:United StatesArgentinaAustraliaAustriaBelgiumCanadaChileDenmarkFranceGermanyGreeceHungaryIsraelItalyJapanNew ZealandPolandPortugalSouth KoreaSpainTaiwanTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria

Frequently asked questions about ALIS

What is ALIS used for?

ALIS, also known as amikacin liposome inhalation suspension, is used for nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex. It is an investigational small molecule in Phase 3 clinical development for this indication. ALIS is being developed by Insmed Incorporated.

How does ALIS work?

ALIS is a liposomal formulation of amikacin, an aminoglycoside antibiotic. It delivers amikacin directly to the lungs via inhalation, targeting Mycobacterium avium complex infections. The liposome encapsulation is designed to enhance drug delivery and uptake by macrophages, where the bacteria reside.

Who makes ALIS?

ALIS is developed by Insmed Incorporated, a biopharmaceutical company. Insmed is focused on developing therapies for serious and rare diseases. The company's ticker symbol is INSM.

What phase is ALIS in?

ALIS is in Phase 3 clinical development. It has completed two Phase 3 trials for nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex. ALIS is not yet approved by regulatory authorities and remains investigational.

What clinical trials is ALIS in?

ALIS has completed two Phase 3 trials. NCT04677543 evaluated patient-reported outcomes in 99 participants, and NCT04677569 assessed ALIS in 425 participants with nontuberculous mycobacterial lung infection. Both trials were randomized, double-blind, and placebo-controlled, enrolling adults in multiple countries.

Is ALIS the same as amikacin liposome inhalation suspension?

Yes, ALIS is the same as amikacin liposome inhalation suspension. The drug is a liposomal formulation of amikacin, an antibiotic, delivered via inhalation for the treatment of nontuberculous mycobacterial lung infections caused by Mycobacterium avium complex.